Recombinant human papillomavirus bivalent vaccine

{
  "id": "MLC-T-ONC-007256",
  "term": "Recombinant human papillomavirus bivalent vaccine",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A vaccine that is no longer available in the United States but is still used in other countries to protect against infection with two types of human papillomavirus (HPV). Recombinant human papillomavirus bivalent vaccine is used in females aged 9 to 25 years to protect against high-risk HPV types 16 and 18, which most often cause cervical cancer and lesions that may become cervical cancer. Recombinant human papillomavirus bivalent vaccine may also prevent other HPV-related cancers. Also called Cervarix.",
    "A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, recombinant human papillomavirus bivalent vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection."
  ],
  "abbreviation": "HPV 16/18 L1 VLP/AS04 VAC",
  "synonyms": [
    "Cervarix",
    "human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/recombinant-human-papillomavirus-bivalent-vaccine/"
}